MeSH tree: D12.776.543.750.705.852.760
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II ...
Apr 20, 2026
0
3
For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar brand names. However, ...
Feb 20, 2026
0
7
Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that recognizes two distinct ...
Jan 8, 2026
0
35
Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression ...
Dec 9, 2025
0
9
In the absence of much federal action, states have enacted dozens of laws this year to lower prescription drug costs for their residents—and many more are considering following suit.
Nov 4, 2025
0
14
The first international trial of an unproven stroke treatment available in the U.S. has concluded that, while harmless, "perispinal" etanercept—injected into the spinal area—is no more effective than an inactive dummy drug, ...
Sep 19, 2025
0
39
Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great disappointment.
Aug 14, 2025
0
73
1 in 100 people in Britain today live with rheumatoid arthritis (RA). Unlike osteoarthritis (OA), RA is caused not by wear and tear but by the body's immune system attacking its own joints. RA can strike quickly at any age—but ...
Jul 3, 2025
0
46
Radionuclide therapy with the radioactive element terbium could effectively combat lymphoma. This is demonstrated by promising results from experiments carried out at the Paul Scherrer Institute PSI in collaboration with ...
Jun 2, 2025
0
27
A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the "tumor-immune-gut axis," and its role in influencing immunotherapy responses in patients with recurrent ovarian ...
Dec 13, 2024
0
50
